BRCA-I and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling

Cancer Treatment Reviews

Volumn 27, Issue 5, 2001, Pages 295-304

  Nicoletto, M O ^a   Donach, M ^a   De Nicolo, A ^a   Artioli, G ^a   Banna, G ^a   Monfardini, S ^a  

^a Padua City Hospital   (Italy)

Author keywords

BRCA 2; BRCA I; Clinical practice; Genetic counselling; Mutations; Prognostic factors; Review

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC DISORDER; GENETIC HETEROGENEITY; HUMAN; INFORMED CONSENT; LIFESPAN; MENOPAUSE; OVARY CANCER; PATIENT REFERRAL; PHENOTYPE; PROGNOSIS; RISK ASSESSMENT; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MUTATION; ONCOLOGY; PATHOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL ONCOLOGY; MUTATION; PROGNOSIS;

EID: 0034747049     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0233     Document Type: Article

References (86)

1. Screening for hereditary cancer and genetic testing, epitomised by breast cancer
2. Germ line p53 mutations in a familial sindrome of breast cancer, sarcomas, and other neoplasms
3. Genetic predisposition to breast cancer: A surgical perspective
4. Disruption of the ATM gene in breast cancer
5. Germline mutations of the PTEN gene in a Japanese patient with Cowden's disease
6. Male breast cancer in Cowden syndrome patients with germline PTEN mutations
7. Tumor suppressor genes and breast cancer
8. Breast and ovarian cancer incidence in BRCA-1 mutation carriers
9. Frequency of BRCA1-BRCA2 mutations in a population-based sample of young breast carcinoma cases
10. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
11. BRCA1 mutations and breast cancer in the general population: Analysis in women before age 35 years and in women before age 45 years with first-degree family history
12. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
13. Genetic heterogeneity and penetrance analysis of the BRCA-1 and BRCA-2 genes in breast cancer families
14. Age at onset for familial epithelial ovarian cancer
15. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers
16. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients
17. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
18. Natural history of hereditary cancer of the breast and colon
19. BRCA-associated breast cancer in young women
20. Survival in hereditary breast cancer associated with germline mutations of BRCA2
21. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
22. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
23. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer
24. Histoprognostic grade in BRCA1-associated breast cancer
25. Histopathology of breast cancer in relatinn to age
26. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, BRCA1/p53, and Brca2/p53 nullizygous embryos
27. Tumour biological features of BRCA1-induced breast and ovarian cancer
28. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study
29. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers. A population-based study
30. Pathobiologic characteristics of hereditary breast cancer
31. Mutations at BRCA1: The medullary breast carcinoma revisited
32. Novel indications for BRCA1 screening using individual clinical and morphological features
33. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumors
34. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women
35. Frequency of p53 mutations in breast carcinomas of Ashkenazi Jewish BRCA1 mutation carriers
36. ErbB2 oncogene in human breast cancer and its clinical significance
37. Clinical activity of Trastuzumab and Vinorelbine in women with HER2-overexpressing metastatic breast cancer
38. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
39. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
40. Inherited BRCA2 mutation associated with high grade breast cancer
41. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies
42. Incessant ovulation - A factor in ovarian neoplasia?
43. Factors in the causation and incidence of ovarian cancer
44. Risk modifiers in carriers of BRCA-1 mutations
45. The impact of history on ovarian cancer risk: The Utah population database
46. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
47. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
48. Survival in early-onset BRCA1 breast-cancer patients
49. Multifactorial analysis of differences between sporadic breast cancer and cancers involving BRCA1 and BRCA2 mutations
50. Survival and tumour characteristics of breast-cancer patients with germ-line mutation of BRCA1
51. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability
52. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
53. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21
54. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations
55. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1
56. Familial ovarian cancer
57. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
58. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?
59. Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene
60. Survival of patients with breast cancer and BRCA1 mutations
61. No deleterious effects of radiotherapy in women who are heterozygote for a BRCA-1 or BRCA-2 mutation following breast-conserving therapy
62. Survival and tumor characteristics of German hereditary breast cancer patients
63. Genetic prognostic markers for colorectal cancer
64. Better survival rates in patients with MLH1-associated hereditary colorectal cancer
65. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer
66. Risks of cancer in BRCA-1 mutation carriers
67. The genetic attributable risk of breast and ovarian cancer
68. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
69. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene
70. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes
71. Oral contraceptives and the risk of hereditary ovarian cancer
72. Can Fenretinide protect women against ovarian cancer?
73. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families
74. Genetic counselling in the cancer family clinic
75. Genetic counselling for familial cancer risk
76. BRCA1/2 Testing: Complex themes in result interpretation
77. Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II BRCA1 and BRCA2
78. Ovarian cancer screening: The role of ultrasound in early detection
79. Elevation of multiple serum markers in patients with stage I ovarian cancer
80. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR
81. Detection of pre-malignant and malignant breast cells by ductal lavage
82. False-positive results in dynamic MR mammography
83. MR imaging: Its current and potential utility in the diagnosis and management of breast cancer
84. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American society of clinical oncology
85. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer